abstract |
The present invention relates to: a novel chimeric antigen receptor using a CD99 region participating in immune synapse stabilization as a backbone of the chimeric antigen receptor; immune cells comprising same; and uses thereof. Compared to CAR-T cells with the existing backbone, CD99-based CAR-T cells form a significantly more stable immune synapse with tumor cells and show improved treatment efficiency on tumors, and thus can be advantageously used for immune cell therapy for cancer treatment. |